A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. - Wikidata - wikimedia - TriplyDB

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.

http://www.wikidata.org/entity/Q37232214

about

Defining response to anti-VEGF therapies in neovascular AMD Developments in Ocular Genetics: 2013 Annual Review IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis.Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

P2860

Q26996510-E26C3F71-8DAB-4135-BF39-1DD284C35BF5 Q33991982-D2B31947-0DD2-4716-8074-CB1A756F7D5E Q37031844-236954DF-55B4-407D-906E-CDAED7FCF3DA Q39235857-45F400EC-DE43-4EB6-82F9-7F51F77724EA Q41504310-FA44C93D-ACD3-4DF6-9314-C2253A830A15 Q41833477-FA4C9BBD-6397-45D6-BE07-344D835AAB58 Q51759447-4FE89B9B-8665-443D-81A1-BCB0518C6810 Q52559837-5661A6BD-81D7-4F6E-847C-846D0226C687

P2860

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.

http://www.wikidata.org/entity/Q37232214

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A pharmacogenetics study to pr ...... related macular degeneration.

@en

A pharmacogenetics study to pr ...... related macular degeneration.

@nl

type

label

A pharmacogenetics study to pr ...... related macular degeneration.

@en

A pharmacogenetics study to pr ...... related macular degeneration.

@nl

prefLabel

A pharmacogenetics study to pr ...... related macular degeneration.

@en

A pharmacogenetics study to pr ...... related macular degeneration.

@nl

P1433

Q37232214-5CE53AF7-1440-4EDC-AD53-F92F899B06FC

P1476

Q37232214-8E71B3C8-9C11-45AF-BCB8-2FDC176E2BC4

P2093

Q37232214-1107C794-BCF5-4DF0-A723-3DBEB2A6FABC

Q37232214-1BF0AB43-6351-427C-835A-D431BB350201

Q37232214-1F3794F9-6B73-4151-91E1-4C47F2504A13

Q37232214-5436336C-6A6F-4D0F-BAA5-454FBB7561CE

Q37232214-6A28FEEB-7A4B-487F-AAD6-35D657EB8899

Q37232214-873A067C-8174-4C2C-8931-73951D53A698

Q37232214-8741A78B-6DF0-413F-8297-7A58224E6A6F

Q37232214-875056CA-0B93-4F0C-8798-2B7D12393B19

Q37232214-968B0492-22CA-4C8B-8BA0-CCEEB1A144BF

Q37232214-AFE6A7E5-085C-4D54-BF2F-B0C075E45C4B

P2860

Q37232214-0BC8FA85-3EFC-4CFF-8B52-03E93C4EC8E3

Q37232214-21666E42-AB2D-4C92-AE61-3E85E68FAD7A

Q37232214-358BE010-B048-46D4-837A-414A13A82678

Q37232214-3B54D0F6-0A3E-4DD4-B62D-3823F101AC93

Q37232214-3E021168-35E4-42D8-9466-3119237C3D49

Q37232214-90C3D47F-3CB8-4A92-89CF-3D9C2B89C16C

Q37232214-A98E1950-970A-4487-AF53-0D8E852B91A2

Q37232214-ACB87A55-31DC-48AC-AC89-8246184D90BF

Q37232214-B1F8F3F6-CC65-425B-A4C3-3537040EDBE9

Q37232214-B990DD06-A23B-448A-8DDE-0A0A08F929DA

P304

Q37232214-14957DB3-3ABA-47DD-B4A1-CB8FE2D23B25

P31

Q37232214-D41EE04B-771F-48D5-8885-D548B52FDA3D

P356

Q37232214-2148A242-52D7-4B0E-886E-75B8B9206844

P407

Q37232214-6CDA03AB-4B3E-4DDE-8F28-FA25FA3A6BAF

P478

Q37232214-E9C5A7BB-CBDA-4718-BAB3-580A90DA98FA

P577

Q37232214-6F97FF51-E360-4A28-BB93-58CFBD848CFA

P698

Q37232214-081AA57A-D000-4F2D-9A1E-90F80DB79C0C

P932

Q37232214-A062B445-35E8-4AFA-851B-127A041F4D80

P356

P1433

Clinical Ophthalmology

P1476

A pharmacogenetics study to pr ...... related macular degeneration.

@en

P2093

Brad A Hancock

http://www.w3.org/2001/XMLSchema#string

Bryan P Schneider

http://www.w3.org/2001/XMLSchema#string

Edward Wood

http://www.w3.org/2001/XMLSchema#string

John W Kitchens

http://www.w3.org/2001/XMLSchema#string

Josh Waymire

http://www.w3.org/2001/XMLSchema#string

Lang Li

http://www.w3.org/2001/XMLSchema#string

Milan Radovich

http://www.w3.org/2001/XMLSchema#string

Nawal Kassem

http://www.w3.org/2001/XMLSchema#string

Rick Isernhagen

http://www.w3.org/2001/XMLSchema#string

Thomas W Stone

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Prevalence of age-related macular degeneration in the United States

Ranibizumab for neovascular age-related macular degeneration

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.

Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.

P304

1987-1993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S39635

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24143065

http://www.w3.org/2001/XMLSchema#string

P932

3797648

http://www.w3.org/2001/XMLSchema#string